
Factors Linked to Survival Outcomes in Mets Breast Cancer
TOPLINE: In patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (ERBB2)–negative metastatic breast cancer who progressed following endocrine plus cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy, longer …